Literature DB >> 3912192

Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man.

S Edsbäcker, K E Andersson, A Ryrfeldt.   

Abstract

Budesonide, a topically potent glucocorticoid, was administered to 4 healthy volunteers by i.v. infusion and by nasal instillation of 100 micrograms tritium-labelled drug. Plasma was analyzed by liquid chromatography plus scintillation counting of collected fractions. After i.v. administration the plasma clearance was 0.921/min and the apparent volume of distribution was 2.81/kg. After nasal administration, the time to reach the peak plasma level was approximately 30 min, and the systemic availability was 102%. Budesonide had marginal effects on plasma cortisol and white blood cell counts either after i.v. or nasal administration. Thus, nasally instilled budesonide in solution is rapidly and completely absorbed from the nasal mucosa. The systemic effects after this clinically recommended nasal dose were negligible.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3912192     DOI: 10.1007/bf00613465

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  30 in total

1.  Dose-dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J C Loo; I J McGilveray; N Jordan; J Moffat; R Brien
Journal:  J Pharm Pharmacol       Date:  1978-11       Impact factor: 3.765

2.  Dose-dependent prednisolone kinetics.

Authors:  A Tanner; F Bochner; J Caffin; J Halliday; L Powell
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

3.  A comparative trial testing budesonide and flunisolide nasal sprays in patients with seasonal allergic rhinitis.

Authors:  U Pipkorn; A Geterud
Journal:  Ann Allergy       Date:  1984-03

4.  Kinetics of the epimeric glucocorticoid budesonide.

Authors:  A Ryrfeldt; S Edsbäcker; R Pauwels
Journal:  Clin Pharmacol Ther       Date:  1984-04       Impact factor: 6.875

5.  Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids.

Authors:  E Dahlberg; A Thalén; R Brattsand; J A Gustafsson; U Johansson; K Roempke; T Saartok
Journal:  Mol Pharmacol       Date:  1984-01       Impact factor: 4.436

6.  Deposition of pressurised aerosols in the human respiratory tract.

Authors:  S P Newman; D Pavia; F Morén; N F Sheahan; S W Clarke
Journal:  Thorax       Date:  1981-01       Impact factor: 9.139

7.  Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17 alpha,21-dipropionate in human liver and lung homogenate.

Authors:  P Andersson; A Ryrfeldt
Journal:  J Pharm Pharmacol       Date:  1984-11       Impact factor: 3.765

8.  Prednisolone clearance at steady state in man.

Authors:  U F Legler; F J Frey; L Z Benet
Journal:  J Clin Endocrinol Metab       Date:  1982-10       Impact factor: 5.958

9.  Budesonide - a new nasal steroid.

Authors:  U Pipkorn; H Rundcrantz; N Lindqvist
Journal:  Rhinology       Date:  1980-12       Impact factor: 3.681

10.  Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man.

Authors:  S A Johansson; K E Andersson; R Brattsand; E Gruvstad; P Hedner
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more
  13 in total

1.  Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder.

Authors:  L Thorsson; O Borgâ; S Edsbäcker
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

2.  Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung.

Authors:  C Minto; B Li; B Tattam; K Brown; J P Seale; R Donnelly
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

3.  The impact of corticosteroids on growth and bone health.

Authors:  T Mushtaq; S F Ahmed
Journal:  Arch Dis Child       Date:  2002-08       Impact factor: 3.791

4.  Absolute bioavailability of nicotine applied to different nasal regions.

Authors:  C J Johansson; P Olsson; M Bende; T Carlsson; P O Gunnarsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Rectal pharmacokinetics of budesonide.

Authors:  K Dahlstrom; S Edsbacker; A Kallen
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 6.  Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids.

Authors:  B J Lipworth; J R Seckl
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

Review 7.  Clinical pharmacokinetics of inhaled budesonide.

Authors:  R Donnelly; J P Seale
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 8.  Inhaled beta-2 agonists and steroids. Present state and future perspectives.

Authors:  A M Clauzel
Journal:  Clin Rev Allergy       Date:  1994

Review 9.  A risk-benefit assessment of intranasal triamcinolone acetonide in allergic rhinitis.

Authors:  S M Gawchik; C L Saccar
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

10.  Linking Suspension Nasal Spray Drug Deposition Patterns to Pharmacokinetic Profiles: A Proof-of-Concept Study Using Computational Fluid Dynamics.

Authors:  Alex Rygg; Michael Hindle; P Worth Longest
Journal:  J Pharm Sci       Date:  2016-06       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.